Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ted William Johnson"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Aaron N. Hata, Jennifer L Peterson, Scott L. Weinrich, Satoshi Yoda, Jessica J. Lin, Adam Acker, Aya Shiba-Ishii, Ibiayi Dagogo-Jack, Lesli A. Kiedrowski, Justin F. Gainor, Kristin Dionne, Michele McTigue, Andrew Do, Makeba A Walcott, Mari Mino-Kenudson, Jaimie L. Barth, Ted William Johnson, Beow Y. Yeap, Ping Wei, Linh Nguyen-Phuong, Theodore R. Johnson
The treatment approach to advanced, ALK-positive non-small cell lung cancer (NSCLC) utilizing sequential ALK tyrosine kinase inhibitors (TKIs) represents a paradigm of precision oncology. Lorlatinib is currently the most advanced, potent and selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a276b417464b334652691d18f8ae4c0
https://doi.org/10.1101/2021.07.16.452681
https://doi.org/10.1101/2021.07.16.452681
Autor:
Sergei Timofeevski, Sansana Sawasdikosol, Timothy Scott Fisher, Steven J. Burakoff, Robert Steven Kania, Ted William Johnson, Gallego Rebecca Anne, Ciarán N. Cronin, Eric Johnson, Michele McTigue, Michael F. Maestre
Publikováno v:
J Biol Chem
Hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) is a Ser/Thr kinase that operates via the c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling pathways to dampen the T-cell response and antitumor immunity. Accord
Autor:
Dan Gehlhaar, Alexei Brooun, Mehran Jalaie, Michele McTigue, Sergei Timofeevski, Ben Bolaños, Gallego Rebecca Anne, Ted William Johnson
Publikováno v:
ACS medicinal chemistry letters. 9(9)
[Image: see text] Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that can become oncogenic by activating mutations or overexpression. Full kinetic characterization of both phosphorylated and nonphosphorylated wildtype and mutant ALK k
[Image: see text] Structure-based drug design (SBDD) is commonly leveraged in rational drug design. Usually, ligand and binding site atomic coordinates from crystallographic data are exploited to optimize potency and selectivity. In addition to tradi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::433858d7f4acc4552a7679cee53ca01a
https://europepmc.org/articles/PMC6142050/
https://europepmc.org/articles/PMC6142050/
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr
Publikováno v:
Practical Medicinal Chemistry with Macrocycles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e544b7dde95a547c39ed9b34f43ce80
https://doi.org/10.1002/9781119092599.ch18
https://doi.org/10.1002/9781119092599.ch18
Autor:
Paul G. Richardson, Phuong Le, Benjamin J. Burke, Ted William Johnson, Sacha Ninkovic, Ketan S. Gajiwala, Maria Angelica Linton
Publikováno v:
Bioorganic & Medicinal Chemistry. 23:3408-3413
Incorporation of nitrogen is a common medicinal chemistry tactic to reduce log D values. Neighboring group participation influences log D , so the results are isomer dependent. The log D and log P differences observed between isomeric pyrimidines 1 ,
Autor:
Wenyue Hu, Rosa L. Frias, Hovhannes J. Gukasyan, Alice T. Shaw, Valeria Fantin, Ryohei Katayama, Nathan V. Lee, Ruth W. Tang, Timothy Affolter, Eugene Lifshits, Ted William Johnson, Divya Bezwada, David P. Kodack, Lars D. Engstrom, Hieu Lam, Sidra Mahmood, Tod Smeal, Luc Friboulet, Rakesh K. Jain, Hui Wang, Melissa West, Dac M. Dinh, Bhushankumar Patel, Qiuhua Li, Konstantinos Tsaparikos, Helen Y. Zou, Justine L. Lam, Sergei Timofeevski, Shinji Yamazaki, Patrick B. Lappin, Justin F. Gainor, Shibing Deng, Jinwei Wang
Publikováno v:
Cancer Cell. 28:70-81
SummaryWe report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mut
Autor:
Melissa West, Victoria A. Appleman, Valeria Fantin, Michele McTigue, Sergei Timofeevski, Matthew D. Falk, Alexei Brooun, Scott Rp McDonnell, Tod Smeal, Al Charest, Wenyue Hu, Wei Liu, Ya-Li Deng, Katy A. Wong, Timothy C. Nichols, Justine L. Lam, Ping Jiang, Helen Y. Zou, Qiuhua Li, Lars D. Engstrom, Timothy Affolter, Ted William Johnson, Patrick B. Lappin
Publikováno v:
Proceedings of the National Academy of Sciences. 112:3493-3498
Oncogenic c-ros oncogene1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clinical activit